Skip to main content

Table 4 Bleeding control by treated site

From: Clinically significant bleeding in incurable cancer patients: effectiveness of hemostatic radiotherapy

Treated Site (N)

Change in grade

Baseline to End of RT n (%)

Baseline to End of follow-up n (%)

End of RT to End of follow-up n (%)

Uterovaginal (N=19)

Worsened

-

1 (5.3%)

2 (10.5%)

 

No change

1 (5.3%)

1 (5.3%)

10 (52.6%)

 

Improved

18 (94.7%)

15 (78.9%)

5 (26.3%)

 

Missing

-

2 (10.5%)

2 (10.5%)

Bladder (N=17)

Worsened

-

2 (11.8%)

5 (29.4%)

 

No change

6 (35.3%)

4 (23.5%)

8 (47.1%)

 

Improved

11 (64.7%)

10 (58.8%)

3 (17.6%)

 

Missing

-

1 (5.9%)

1 (5.9%)

Lung (N=10)

Worsened

-

-

-

 

No change

-

-

6 (60.0%)

 

Improved

10 (100.0%)

8 (80.0%)

2 (20.0%)

 

Missing

-

2 (20.0%)

2 (20.0%)

Upper GI (N=10)

Worsened

1 (10.0%)

3 (30.0%)

2 (20.0%)

 

No change

-

-

4 (40.0%)

 

Improved

9 (90.0%)

6 (60.0%)

3 (30.0%)

 

Missing

-

1 (10.0%)

1 (10.0%)

Other (N=6)*

Worsened

-

-

-

 

No change

-

-

5 (83.3%)

 

Improved

6 (100.0%)

6 (100.0%)

1 (16.7%)

  1. Abbreviations: *including lower gastrointestinal (n=4), skin (n=1) and abdominal wall (n=1).